QuiaPEG

About

 
Board of directors
Management team
Company overview

Management Team

Mr. Marcus Bosson 

CHIEF EXECUTIVE OFFICER
Marcus Bosson, M.Sc., SSE, has a background from the venture capital industry as well as from the biotechnology industry as a founder of several successful companies. Mr. Bosson has raised approximately MUSD 100 in venture capital to companies founded by him. Mr. Bosson is currently CEO of QuiaPEG Pharmaceuctials AB, a company he co-founded in 2012.

Dr. Marek Kwiatkowski 

CHIEF SCIENTIFIC OFFICER
Dr. Kwiatkowski currently serves as Associated Professor at the Department of Bioorganic Chemistry at Uppsala University, Sweden. Dr. Kwiatkowski completed his studies in chemistry and biophysics at the Jagiellonian University, Poland and received his Ph.D. concerning RNA chemistry at the Institute for Bioorganic Chemistry at Uppsala University, Sweden, in 1984. He has worked for large international companies as well as small start-ups and most recently he worked at Department of Medical Genetics and Department of Cell and Molecular Biology at Uppsala University. Dr. Kwiatkowski is co-author of over 70 scientific papers and inventor of 28 issued patents.

 

Senior Scientific Advisors

Dr. James M. Van Alstine 

SENIOR SCIENTIFIC ADVISOR
James M. Van Alstine is acting as a Senior Scientific Advisor to QuiaPEG. Dr. Van Alstine holds a B. Sc. in Biochemistry and a Ph. D. in Experimental Pathology from the University of British Columbia in Vancouver. For many years he was a Professor at the University of Alabama in Huntsville, and a colleague of Prof. J. Milton Harris who founded Shearwater Polymers (now part of Nektar Corporation). They published many key papers on modification of proteins and surfaces with polymers such as "PEG". Dr. Van Alstine moved to Stockholm in the 1990´s and was a Professor at the Royal Institute of Technology prior to joining GE Healthcare in Uppsala in 2000. 

Over the next 14 years Jim played a senior scientific role in the development of bioseparations products, including chromatography resins for purification of PEG-modified proteins. He was also heavily involved in technology evaluation and sourcing, and the R&D to Marketing interface. In 2014 Jim started his own consulting company JMVA Biotech AB. 

He is the author of approximately 100 scientific papers, including several key reviews on PEGylation technology and is listed as inventor on over 50 national patents covering over 20 patent families. He currently reviews for a number of international scientific journals including J. Chromatography, Biotechnology and Bioengineering, and J. Colloid and Interface Science.

Vidar Wendel-Hansen 

CONSULTANT, DRUG DEVELOPMENT

Vidar has an MD, PhD from Karolinska Institutet, a Diploma in Pharmaceutical Medicine and more than 20 years of industrial life science experience from positions within molecular diagnostics, pre-clinical and clinical development and medical affairs. Vidar has worked for large corporations such as Pharmacia Biotech, Gilead Sciences and Novartis as well as small biotech start-ups within several different therapeutic areas such as metabolism, infectious diseases, vaccines, oncology and neuroscience. He has also worked as a clinical assessor of anti-infective drugs and vaccines at the Swedish Medical Products Agency. Vidar is an experienced project manager and team leader, co-author of 11 scientific papers and co-inventor of 4 patents.

Mats Reslow 

CONSULTANT, DRUG DEVELOPMENT

Mats Reslow has a Ph.D. in Biotechnology from Faculty of Engineering LTH at Lund University. He has a long career within drug delivery in several companies; Pharmacia, Ferring, Bioglan, SkyePharma and NovoNordisk. Mats Reslow has worked as head of development groups and project leader in different projects within drug delivery for once-weekly and once-monthly formulations of peptides and proteins where several projects have reached clinical development and the market.

Between 2004 and 2016 Mats Reslow worked at Novo Nordisk as a specialist and project manager within drug delivery and protein formulation. The goal for many of these projects was to increase the half-life of proteins with pegylation or conjugation with fatty acids. He is an author of 22 scientific papers and main inventor or coinventor of 27 patents, some within formulation of pegylated proteins. Mats Reslow now work as an independent consultant for several biotech companies in Sweden.

Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message